Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Study Validates Use of Vectra DA Test as an Objective Measure of RA Disease Activity

Published: Thursday, July 12, 2012
Last Updated: Wednesday, July 11, 2012
Bookmark and Share
Results published in Arthritis Care & Research support adoption of multi-biomarker blood test in combination with clinical assessment.

Crescendo Bioscience®, Inc. has announced the online publication of results validating the performance of Vectra™ DA to measure rheumatoid arthritis (RA) disease activity in Arthritis Care & Research, an official journal of the American College of Rheumatology (ACR).

Vectra DA is the only multi-biomarker blood test for RA disease activity that simultaneously integrates 12 key proteins consistently associated with RA disease activity into a single, objective and quantitative score to help physicians make more informed treatment decisions.

The study results demonstrate that Vectra DA has a statistically significant association with other validated clinical disease activity measures.

Moreover, changes in the Vectra DA algorithm score tracked over time significantly discriminated between clinical responders and non-responders to RA therapy such as TNF antagonists and methotrexate (MTX).

“Current RA treatment guidelines from the American College of Rheumatology recommend periodic quantitative disease assessment as an important component in any treatment plan for patients with RA,” said Jeffrey R. Curtis, MD, MS, MPH, lead author of the manuscript and director of the University of Alabama at Birmingham’s Arthritis Clinical Intervention Program.

Curtis continued, “This study shows that Vectra DA provides a valid and objective measure of disease activity. The results support the use of Vectra DA as a complement to existing clinical assessments to help clinicians assess disease activity over time and in response to RA treatments so as to impact care as well as potentially improve patient outcomes.”

Vectra DA was designed to be used in conjunction with existing clinical assessment measures, bringing the crucial understanding of individual disease biology into the mix of factors doctors traditionally consider before proposing or changing treatment plans.

The additional insight provided by Vectra DA has the potential to alert physicians to disease activity that is otherwise difficult to detect, given the limitations of clinical assessment methods developed over the last 30 years.

Study Results
The study found that Vectra DA’s multi-biomarker disease activity score had a statistically significant association (p<0.001) with DAS28-CRP, a composite algorithm score for the clinical assessment of RA disease activity that is commonly used in RA clinical trials.

The validity of the test was established in both seropositive patients (positive for either rheumatoid factor and/or anti-cyclic citrullinated peptide antibodies) and seronegative patients (negative for both).

Further, for patients initiating methotrexate or anti-TNF therapy, changes in the Vectra DA algorithm score were shown to be significantly associated with changes in clinically-assessed disease activity (p<0.001) and discriminated between clinical responders and non-responders to therapy. These findings confirm the validity of Vectra DA as an objective measure of RA disease activity to help inform patient management decisions.

“Based on the reported real-world experiences, and the study data reported to date, we believe Vectra DA represents a valuable new tool that has the potential to transform how rheumatologists manage RA patients,” said Oscar Segurado, MD, PhD, Chief Medical Officer at Crescendo Bioscience.

Segurado continued, “Importantly, it is the only quantitative metric available to these doctors that provides an objective value that can assess patients in different practice settings, or the same patients tracked over time, with an unprecedented level of precision and reproducibility. To date, Vectra DA has been ordered by over 400 US rheumatologists to inform the assessment of over 20,000 RA patients.”

Study Design
Serum samples from a total of 426 patients that were independent of prior research, both seropositive (230) and seronegative (196), were selected from three cohorts: the Index for Rheumatoid Arthritis Measurement [INFORM] (US), the Brigham and Women’s Hospital Rheumatoid Arthritis Sequential Study Registry [BRASS] (US), and the Leiden Early Arthritis Clinic cohort (Netherlands).

The study was designed to validate and evaluate the performance of Vectra DA compared to other clinical disease activity measures in both seropositive and seronegative patient groups.

The cross-sectional and longitudinal relationships between the Vectra DA score and clinical disease activity assessments were characterized separately in both seropositive and seronegative patient groups.

The changes associated with the Vectra DA algorithm score and clinical responses 6-12 weeks after initiation of anti-TNF or MTX treatment were evaluated in a separate cohort of 45 patients enrolled in BRASS.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Crescendo Bioscience® Secures $28 Million in Series D Financing
Vectra™ DA used in more than 30,000 patients in 2012 milestone.
Friday, January 04, 2013
Scientific News
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.
Biomarker Finder Adjusts On the Fly
Rice University scientists build better tool to find signs of disease.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos